Heads on! Designing a Qualification Framework for Organ-on-Chip
Open accessThe DOI matches its Crossref record; 4 of the 6 references it cites were found in a registry or an index.
Abstract
Expert feedbackThe key starting point for obtaining regulatory uptake of an OoCbased method is a clear definition of its intended context of use (CoU).Only when the CoU is fully described and understood, does it make sense to start pursuing qualification in a meaningful way.Most OoC models have been developed for biomedical research purposes rather than regulatory applications, thus developers and end-users have to adapt these models and figure out how to use them to address regulatory information requirements.As an example, the same liver OoC model could in principle be used in a preclinical setting to evaluate the metabolic biotransformation of a new drug candidate, its pharmacological efficacy, or its potential to induce liver injury.These represent three general but distinct CoUs, which address different questions that a regulator may have.More refined descriptions of CoU also specify aspects such as therapeutic target group, population variability, and anticipated off-target pharmacology.In addition, CoU includes an indication of what other information sources are used in conjunction with the OoC-derived information, and in that frame, how the OoC results can be interpreted to arrive at a conclusion.In the preclinical assessment of new drug candidates, the context in which efficacy is assessed differs significantly with respect to the assessment of safety.Within the former, the pharmacological effect is already known and thus only therapeutically targeted organs need to be considered.For the latter however, potential off-target effects in non-target organs have to be accounted for, which typically makes it more challenging to employ a single OoC for safety assessment.When devising qualification strategies for OoC methods used in efficacy or safety studies, the relevant exposure scenario has to be considered, including the nominal dose, the route of exposure (e.g., dermal, inhalation or oral), and whether the drug is administered once or repeatedly over a period of time.For efficacy assessment, the comparative standard is usually the treatment applied in clinical practice, thus in-vivo-to-in-vitro extrapolation and related allometric-type scaling are required to ensure an equivalent internal dosing scenario within the OoC model.A satisfactory level of qualification can only be achieved with a sufficient level of standardization, and vice versa.Thus, the development of OoC qualification frameworks and associated criteria should both reflect and influence ongoing efforts to address standardization of OoC (Piergiovanni et al., 2021a,b).Standards
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Developers of OoC models typically do not consider standardization and regulation early in their design process, hindering their possible future development into products that are qualified for use in commercial and regulatory contexts (Leung et al., 2022; Piergiovanni et al., 2024).”
From Considering future qualification for regulatory science in the early development of microphysiological systems: a case study of microthrombosis in a Vessel-on-Chip (2024) · cites this paper as Piergiovanni et al., 2024
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The publisher hasn’t deposited this paper’s reference list.
Research works printed but not linked: 1
- Tomlinson, L., Ramsden, D., Leite, S. B. et al. (2023). Consid- erations from an international regulatory and pharmaceutical industry (IQ MPS Affiliate) workshop on the standardization
Cited by
Roadblocks confronting widespread dissemination and deployment of Organs on Chips
Alver, C. G., Drabbe, E., Ishahak, M., & Agarwal, A. (2024) · Nature Communications · doi:10.1038/s41467-024-48864-3 · Cited by 74
“Quali fi cation process is also intended to explain how results of the approach will be used in decision-making 88 .”
MethodFabrication of organ-on-a-chip using microfluidics
Ying-Jin, S., Yuste, I., González‐Burgos, E., & Serrano, D. R. (2025) · Bioprinting · doi:10.1016/j.bprint.2025.e00394 · Cited by 36
Weener, H. J., Middelkamp, H. H. T., & Van der Meer, A. D. (2024) · Frontiers in Toxicology · doi:10.3389/ftox.2024.1513002 · Cited by 10
New approach methodologies for risk assessment of urinary occurring toxicants
Jobst, M., Guerreiro, I., Payros, D., Oswald, I. P., Fernandes, A. S., Warth, B., & Favero, G. D. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118649 · Cited by 7
de Souza, I. R., Suzukawa, A. A., Horinouchi, C. D. D. S., de Aguiar, A. M., & Dallagiovanna, B. (2024) · In vitro models · doi:10.1007/s44164-024-00076-1 · Cited by 4
Metadata
- Authors
- Piergiovanni, M., Mennecozzi, M., Sampani, S. I., & Whelan, M.
- Affiliations
- Joint Research Centre (IT)
- Venue
- ALTEX
- Publisher
- ALTEX Edition
- Published
- 2024
- Volume
- 41
- Issue
- 2
- Pages
- 320-323
- ISSN
- 0946-7785 (ISSN-L)
- OpenAlex
- W4392251231
- Cited by
- 5
- References
- 0
- Citations by year
- 2025: 2 · 2024: 3
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- cc-by
- Locations
- ALTEX (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Bundesinstitut für Arzneimittel und Medizinprodukte
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Nursing › Issues, ethics and legal aspects › Biomedical Ethics and Regulation
- Keywords
- organ-on-a-chip, qualification frameworks, regulatory acceptance, context of use, liver-on-a-chip, drug safety assessment, drug efficacy evaluation, allometric scaling, standardization, drug-induced liver injury
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.